Therini Bio

Executive Summary

Therini Bio is a clinical-stage biotechnology company pioneering novel immunotherapies for neuroinflammatory diseases driven by vascular dysfunction. The company's approach uniquely targets toxic fibrin deposits, which accumulate in the brain and retina due to blood-brain barrier breakdown, triggering chronic innate immune activation and neuronal damage. This fibrin-targeting mechanism offers a differentiated therapeutic strategy for conditions like Alzheimer's Disease and Diabetic Macular Edema (DME), where neuroinflammation and vascular pathology intersect. Therini's lead program is in Phase 1 clinical development for Alzheimer's, with a second candidate in preclinical development for DME. The company's science is supported by strong preclinical data linking fibrin to neurodegeneration, and its platform has potential applicability across multiple neurological and retinal diseases. As a private, well-funded company founded in 2019, Therini represents a high-risk, high-reward opportunity in the neuroimmunology space, with upcoming clinical data expected to provide key validation of its therapeutic hypothesis. Therini Bio's innovative approach addresses a critical unmet need in diseases with limited treatment options. Alzheimer's Disease affects millions globally, and despite recent anti-amyloid approvals, neuroinflammation remains an undertreated driver. Similarly, current DME therapies focus on VEGF, leaving many patients with persistent inflammation. By specifically targeting toxic fibrin, Therini aims to halt the cycle of inflammation and neurodegeneration. The company's Phase 1 trial will evaluate safety, tolerability, and target engagement in Alzheimer's patients, with initial results expected in the coming months. Success in these early studies could de-risk the platform and attract significant partnership interest. However, as a Phase 1 company with no approved products, Therini faces substantial clinical and regulatory risks. Conviction in the company is moderate at this stage, pending clinical proof-of-concept.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 topline safety data for Alzheimer's candidate60% success
• Q1 2027Initiation of Phase 2 trial in Diabetic Macular Edema50% success
• H2 2026Series C financing or major partnership70% success